Stephanie Gibson
Family · Seneca, SCNPI 1801495494
Payments from drug & device makers
Across 186 payments — averaging $16.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$736
- AstraZeneca$396
- AbbVie$376
- Lilly USA, LLC$323
- GSK$285
- Pfizer$218
- plus $786 from 22 others
What the payments were for
- Food & beverage$3,109100%
- Education$100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 46 | $736 |
| AstraZeneca | 18 | $396 |
| AbbVie | 20 | $376 |
| Lilly USA, LLC | 21 | $323 |
| GSK | 19 | $285 |
| Pfizer | 13 | $218 |
| Bayer | 6 | $98 |
| Dexcom, Inc. | 5 | $83 |
| Exact Sciences | 5 | $75 |
| Phathom Pharmaceuticals, Inc. | 5 | $70 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $48 |
| Boehringer Ingelheim | 3 | $46 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $46 |
| Johnson & Johnson | 3 | $45 |
| Nestle Healthcare Nutrition Inc. | 2 | $31 |
| Xeris Pharmaceuticals, Inc. | 2 | $31 |
| Eisai Inc. | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Lundbeck LLC | 1 | $21 |
| Mylan Specialty L.p. | 1 | $20 |
| Abbott | 1 | $20 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| Amgen | 1 | $18 |
| Novartis | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Merck | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
How this compares
$3,119 in reported general payments places this provider in the 85th percentile of 3,248 family providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 12 | $13,914 |
| MounjaroTirzepatide | 11 | $11,257 |
| EliquisApixaban | 11 | $6,332 |
| Rosuvastatin Calcium | 60 | $1,397 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 30 | $886 |
| Atorvastatin Calcium | 76 | $522 |
| Levothyroxine Sodium | 69 | $485 |
| Oxybutynin Chloride ErOxybutynin Chloride | 11 | $469 |
| Pantoprazole Sodium | 37 | $404 |
| Metoprolol Succinate | 22 | $404 |
| Pravastatin Sodium | 34 | $389 |
| Lisinopril | 71 | $366 |
| Losartan Potassium | 49 | $349 |
| Omeprazole | 37 | $336 |
| Doxycycline Hyclate | 58 | $313 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $46 | $13,91412 claims |
| Lilly USA, LLCMounjaro | $323 | $11,25711 claims |
| PfizerEliquis | $218 | $6,33211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,248 family providers in South Carolina.
Other family in Seneca
- Kristine BoswellSeneca$17K
- Alison FogartyGreenville$2M
- Sara ChristieGreenville$229K
- Kara Cooper GilmerAnderson$127K
- Jessica BellEasley$96K
- Carrie HendersonGreenville$91K
- Sarah ValerioGreer$76K
- Mary WilliamsColumbia$67K
- Michelle StrongGreenville$55K
- Karen McKerihanSummerville$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.